MiNK Therapeutics, Inc.
INKTNext catalyst
agenT-797
Pneumonia
Get an email about INKT's next catalysts
Track MiNK Therapeutics (INKT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
INKT Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.50 | FQ end Sep/2026 | Call: tbd
agenT-797 Phase 2 Est. Readout
Estimated primary completion for agenT-797 trial (NCT07615010) in Pneumonia. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
agenT-797 | Phase 2 | Pneumonia | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in MiNK Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in MiNK Therapeutics, Inc.'s (INKT) pipeline across Phase 2. Its lead program is agenT-797 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MiNK Therapeutics, Inc.'s next FDA catalyst?→
MiNK Therapeutics, Inc.'s (INKT) next tracked catalyst is a Phase 2 readout expected June 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INKT biotech catalysts?→
Add INKT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MiNK Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.